ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,213.49
0.51%
Dow Jones
38,852.27
0.46%
Gold vs US Dollar
2,323.88
1.31%
Brent Oil
83.475
0.42%
Bitcoin
63,465.00
-0.83%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Rigel Pharmaceuticals Inc (RIGL)

  7. Rigel Pharmaceuticals Inc (RIGL) News

Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RIGL
DateTimeSourceHeadlineSymbolCompany
30/04/202413:05PR Newswire (US)Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business UpdateNASDAQ:RIGLRigel Pharmaceuticals Inc
10/04/202421:30PR Newswire (US)Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)NASDAQ:RIGLRigel Pharmaceuticals Inc
04/04/202413:05PR Newswire (US)Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & LymphomaNASDAQ:RIGLRigel Pharmaceuticals Inc
12/03/202412:05PR Newswire (US)Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical OfficerNASDAQ:RIGLRigel Pharmaceuticals Inc
05/03/202421:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RIGLRigel Pharmaceuticals Inc
05/03/202421:06Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RIGLRigel Pharmaceuticals Inc
05/03/202421:01PR Newswire (US)Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:RIGLRigel Pharmaceuticals Inc
02/03/202400:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
02/03/202400:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
02/03/202400:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
02/03/202400:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
27/02/202413:05PR Newswire (US)Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business UpdateNASDAQ:RIGLRigel Pharmaceuticals Inc
22/02/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RIGLRigel Pharmaceuticals Inc
22/02/202412:50PR Newswire (US)Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®NASDAQ:RIGLRigel Pharmaceuticals Inc
14/02/202419:30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RIGLRigel Pharmaceuticals Inc
07/02/202401:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
07/02/202401:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
07/02/202401:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
02/02/202414:56Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RIGLRigel Pharmaceuticals Inc
26/01/202402:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
26/01/202402:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
26/01/202402:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
26/01/202402:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
25/01/202418:48Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RIGLRigel Pharmaceuticals Inc
08/01/202413:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RIGLRigel Pharmaceuticals Inc
08/01/202413:05PR Newswire (US)Rigel Pharmaceuticals Provides Business UpdateNASDAQ:RIGLRigel Pharmaceuticals Inc
05/01/202421:30PR Newswire (US)Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)NASDAQ:RIGLRigel Pharmaceuticals Inc
04/01/202413:05PR Newswire (US)Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in GliomaNASDAQ:RIGLRigel Pharmaceuticals Inc
03/01/202413:05PR Newswire (US)Rigel to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RIGLRigel Pharmaceuticals Inc
08/12/202313:05PR Newswire (US)Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other CancersNASDAQ:RIGLRigel Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:RIGL

Your Recent History

LSE
POS
Plexus
LSE
SBTX
Skinbiotherapeutics
LSE
SRSP
Sirius Petroleum
LSE
RR.
Rolls-royce
LSE
HUM
Hummingbird Resources
LSE
SCE
Surface Transforms
LSE
BIRD
Blackbird
LSE
AAU
Ariana Resources
LSE
AGL
Angle
LSE
CHLL
Chill Brands
LSE
ENET
Ethernity Networks
LSE
LLOY
Lloyds Banking
LSE
ASC
Asos
LSE
GFM
Griffin Mining
LSE
SCLP
Scancell
LSE
GKP
Gulf Keystone Petroleum
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved